Indegene Limited , a digital-first life sciences commercialization company, has reported a strong start to the fiscal year with impressive financial results for the first quarter ended June 30.

Financial Highlights

• Revenue from operations increased by 12.5% year-over-year to ₹7,608.00 million
• EBITDA grew by 15.7% to ₹1,536.00 million, with a margin of 20.2%
• Profit after tax surged by 32.7% to ₹1,164.00 million
• Basic earnings per share improved to ₹4.86 from ₹3.79 in the same quarter last year

Segment Performance

Indegene's business segments showed varied performance:

The company's core segments, Enterprise Commercial Solutions and Enterprise Medical Solutions, demonstrated robust growth of 18.8% and 12.8% year-over-year, respectively. However, the Brand Activation segment (formerly known as Omnichannel Activation) experienced a decline of 8.0%.

Strategic Initiatives and Market Recognition

Indegene has made significant strides in its strategic initiatives:

• The company's 'Tectonic' initiative, aimed at moving upstream in the marketing value chain, has started generating revenue.
• Indegene maintained strong client relationships, with 40 clients contributing over $1 million in revenue.
• The company received recognition from industry analysts, including leadership positions in Everest Group's Life Sciences AI and Analytics Services PEAK Matrix® Assessment and ISG's Provider Lens™ for Life Sciences Digital Services in Commercial Operations.

Management Commentary

Manish Gupta, Chairman and CEO of Indegene, stated, "We continued our growth momentum in Q1, delivering 1.8% growth QoQ in USD. This reflects a strong start to the year and indicates good traction with our clients and from recent deal wins."

Suhas Prabhu, CFO, added, "In Q1, we maintained our trajectory of stable and profitable growth. Both EBITDA margins and PAT margins were on stable lines, even as we continued investing in scaling Tectonic engagements."

Additional Information

• The board approved share allotment under the ESOP 2020 Plan.
• A final dividend of ₹2.00 per share was paid for the financial year 2024-25.
• Total comprehensive income reached ₹1,331.00 million compared to ₹869.00 million in the previous year quarter.

Outlook

Indegene remains focused on its growth strategy, including:

• Strengthening capabilities in Enterprise Commercial Solutions and Enterprise Medical Solutions
• Implementing the Malcolm Baldrige Model to drive operational excellence
• Pursuing M&A opportunities in areas such as Data & Analytics and Medical capability enhancement

The company's strong cash position and balance sheet provide a solid foundation for future growth and expansion initiatives.

Indegene continues to leverage its digital-first approach and deep healthcare expertise to serve the world's top 20 biopharma companies, positioning itself for sustained growth in the evolving life sciences commercialization landscape.

Indegene Limited (BSE: 544172, NSE: INDGN), a digital-first life sciences commercialization company, has achieved a significant milestone in its industry standing. The company has been named a Leader in Life Sciences AI and Analytics Services for Commercial PEAK Matrix® Assessment 2025 by Everest Group, a leading global research and consulting firm.

Key Highlights

• Indegene recognized for its wide-ranging AI and Analytics solutions across life sciences commercial functions
• Everest Group commends Indegene's efforts to embed Generative AI and Agentic AI capabilities in its solutions portfolio
• The assessment evaluated 30 service providers on their AI and Analytics vision, capabilities, and market impact

Indegene's Strengths

Everest Group's assessment highlighted several key strengths of Indegene:

1. Comprehensive AI and Analytics Solutions: Indegene offers a broad portfolio of AI and Analytics solutions tailored for the life sciences commercial sector.

2. Domain Expertise: The company's ability to combine AI and Analytics capabilities with deep domain knowledge was noted as a unique advantage.

3. Specialized Therapy Areas: Indegene delivers contextualized commercial solutions across various therapy areas, including specialty care, oncology, and rare diseases.

4. Innovative AI Integration: The company's continued efforts to embed Generative AI and Agentic AI capabilities across its commercial solutions portfolio were praised.

5. Global Presence: With around 5,000 employees worldwide, 9 operations hubs, and 19 offices across North America, Europe, and Asia, Indegene serves the world's top 20 biopharma companies and many emerging biotech firms.

Industry Impact

Durga Ambati, Practice Director at Everest Group, commented on the evolving landscape of life sciences commercialization: "The growing emphasis on patient- and HCP-centricity to deliver superior customer experiences has modernized commercialization strategies, placing data, analytics, and AI at the core of life sciences enterprises' go-to-market efforts."

Vivek Ghai, EVP-Enterprise Commercial Solutions at Indegene, emphasized the company's focus on responsible AI scaling: "Our focus is on helping clients scale AI responsibly - prioritizing use cases that drive measurable outcomes, integrating seamlessly with enterprise ecosystems, and delivering solutions that are not just innovative, but production-ready from day one."

This recognition by Everest Group underscores Indegene's commitment to innovation and its ability to deliver value to its clients in the rapidly evolving life sciences sector. As the industry continues to embrace AI and analytics, Indegene's leadership position positions it well to support the digital transformation of life sciences companies worldwide.